Indeed, inhibition at the terminal level of the NLRP3 inflammasome axis, IL-1β, with canakinumab (a monoclonal IL-1β antibody) reduced cardiovascular events in the recent CANTOS trial [6], but disturbingly also led to a loss in eGFR in subjects with chronic kidney disease [7]. This evidence concerns the gene IL1B and chronic kidney disease.